MVAC Regimen

Known as: Methotrexate-Vinblastine-Adriamycin-Cisplatin Regimen 
A regimen consisting of methotrexate, vinblastine, doxorubicin and cisplatin used for the treatment of advanced-stage bladder cancer.
National Institutes of Health

Topic mentions per year

Topic mentions per year

1993-2007
0119932007

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
Eight patients with metastatic urothelial carcinoma received high-dose (HD)-MVAC therapy, which consisted of methotrexate (30 mg… (More)
Is this relevant?
2006
2006
OBJECTIVES To report the long-term follow-up of patients with locally advanced bladder cancer treated with either adjuvant… (More)
Is this relevant?
2006
2006
EORTC 30994: randomisierte Phase-IIIStudie zum Vergleich einer sofortigen gegen eine verzögerte Chemotherapie nach radikaler… (More)
Is this relevant?
2005
2005
BACKGROUND The majority of patients with advanced urothelial cancer are elderly, but data regarding this specific age group are… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
Review
2003
Review
2003
For over 15 years, the MVAC regimen (methotrexate/vinblastine/doxorubicin/cisplatin) has been standard chemotherapy for patients… (More)
Is this relevant?
Review
2000
Review
2000
BACKGROUND Inadequate survival results from single agents in the management of advanced bladder cancer have prompted several… (More)
  • table 1
  • table 2
Is this relevant?
1993
1993
PURPOSE This study was undertaken to define an escalated dose schedule of methotrexate, vinblastine, doxorubicin, and cisplatin… (More)
Is this relevant?